Liu Zhen, Teng Xu-Yong, Sun Da-Xin, Xu Wei-Xue, Sun Shao-Long
Department of General Surgery, Shengjing Hospital, China Medical University, Shenyang, China.
Int Surg. 2013 Apr-Jun;98(2):95-100. doi: 10.9738/INTSURG-D-12-00034.1.
Thyroid carcinoma showing thymus-like differentiation (CASTLE) is a kind of rare neoplasm of the thyroid gland. Because thyroid CASTLE is rare and difficult to diagnose, its clinicopathologic features have not been well defined, and no universally accepted treatment recommendation is available. We analyzed retrospectively the clinicopathologic data of 8 patients with thyroid CASTLE who underwent surgery and radiotherapy at the Shengjing Hospital of China Medical University between December 2008 and June 2012. All patients accepted radical surgery. All patients accepted postoperative radiotherapy, except one 79-year-old patient. There was no evidence of recurrence or metastasis during the follow-up period. The pattern of immunohistochemical staining was similar to that of thymic carcinoma. Six of 8 CASTLE cases expressed CD5. All 8 CASTLE patients were negatively expressed in thyroglobulin, thyroid transcription factor 1, and calcitonin. Patients with thyroid CASTLE have good outcomes after radical resection and postoperative radiotherapy. Positive CD5 immunoreactivity can contribute to diagnosis of this disease.
甲状腺癌伴胸腺样分化(CASTLE)是一种罕见的甲状腺肿瘤。由于甲状腺CASTLE罕见且诊断困难,其临床病理特征尚未明确界定,也没有普遍接受的治疗建议。我们回顾性分析了2008年12月至2012年6月在中国医科大学附属盛京医院接受手术和放疗的8例甲状腺CASTLE患者的临床病理资料。所有患者均接受了根治性手术。除1例79岁患者外,所有患者均接受了术后放疗。随访期间无复发或转移迹象。免疫组化染色模式与胸腺癌相似。8例CASTLE病例中有6例表达CD5。8例CASTLE患者的甲状腺球蛋白、甲状腺转录因子1和降钙素均呈阴性表达。甲状腺CASTLE患者根治性切除和术后放疗后预后良好。CD5免疫反应阳性有助于该病的诊断。